Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
This is a Phase 1, open-label, assessor-blind, parallel-group study to evaluate the PK and tolerability of a single subcutaneous dose of 300 milligram (mg) tralokinumab when delivered as a 2 milliliters (mL) injection at different flow rates to healthy adult volunteers.
Age
19–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy males and females ages 19-65 years
Body mass index of 19.0-30.0 kilogram per meter square (kg/m\^2)
No clinically significant abnormality
Vital signs, electrocardiogram (ECG), and laboratory parameters within normal range
Negative alcohol and drug screens
Females of childbearing potential who are sexually active with a nonsterilized male partner must use highly effective contraception
Nonsterilized males who are sexually active with a female partner of childbearing potential must use highly effective contraception.
You may not be if
Concurrent enrollment in another clinical study where the subject is receiving an investigational product
Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives prior to screening, whichever is longer
Receipt of any investigational nonbiologic agent within 3 months or 5 half-lives prior to screening, whichever is longer
Current use of regular pain-modifying, anti-depressant, anxiolytic, or hypnotic medication
History of thrombocytopenia or bleeding disorder or use of anticoagulants
History of any immunodeficiency disorder or use of immunosuppressive medication.
